Fully leveraging the global research and development platform, we have developed a diversified and advanced pipeline, covering more than 20 biosimilars, and bio-innovative candidates, with significant potential for a variety of PD-1/PD-L1-based-immuno-oncology combination therapies. The two R&D facilities located in Shanghai and California ensure the highly productive and cost-efficient R&D processes through close collaboration. We had also assembled a team of over 200 well-trained R&D employees, a large number of whom possess a Ph.D or equivalent degree and have extensive working experience in global large pharmaceutical companies.
We have established a quality management system that covers the entire product lifecycle in accordance with the quality standards of the United States, EU and China. We have a team of over 120 employees who support quality assurance and quality control. Xuhui manufacturing facility, established since 2016, alongwith the supporting quality management system, were granted China and EU GMP Certification. We lead the trend of adopting single-use bioreactors in China. Single-use bioreactors are estimated to generally reduce capital expenditure by up to 50% and production costs by up to 25% to 30%, which distinguishes us with commercial-scale manufacturing capabilities featuring cost advantage and overall quality management.
We have assembled a professional and efficient international commercial team focused on domestic market and established a highly-efficient business operation model in market access, market expansion, sales etc. with the aim of ramping up commercialisation process and driving a robust sales growth. Meanwhile, we have entered into commercialisation agreements with world-renowned pharmaceutical companies including Fosun Pharma, Accord, Cipla, Biosidus, Jacobson etc. to access more markets and realise the mission of “improving patients' lives by timely providing them with quality and affordable protein therapeutics”.
